In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onxeo SA

www.onxeo.com

Latest From Onxeo SA

Finance Watch: Five More Biopharmas Enter US Queue Even As IPO Returns Dip

Public Company Edition: SpringWorks has the biggest IPO ambitions of recent US filers. Also, Deciphera raises $400m after good data and Protalix seeks strategic alternatives.

Financing Strategy

Deals Shaping The Medical Industry, October 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2017.

Deals BioPharmaceutical

Deal Watch: Are Ultragenyx, REGENXBIO In A Bidding War For Dimension?

ProQR spinout Amylon gets started by licensing four central nervous system disorder candidates from its parent, while start-up Eyevance gets US rights to Nicox’s Zerviate.

Deals M & A

Pipeline Watch: Phase III Readouts For ADV7103, Pembrolizumab, Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dental & Oral Products
  • Alias(es)
  • BioAlliance Pharma SA
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Onxeo SA
  • Senior Management
  • Judith Greciet, CEO
    Nicolas Fellmann, CFO
    Françoise Bono, PhD, CSO
    Olivier De Beaumont, CMO
  • Contact Info
  • Onxeo SA
    Phone: (33) 1 45 58 76 00
    49 boulevard du Général Martial Valin
    Paris, 75015
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register